The corporate team at Penningtons Manches Cooper is advising Stanford Capital and SI Capital as joint brokers to ImmuPharma plc on a £6.5 million equity placing of new ordinary shares.
ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE).
Admission of the new shares is expected to occur on 7 September 2020.
London-based corporate partner, Seb Orton, is leading on this deal with assistance from associate Hannah Shamsolmaali.